GSK agreed to an exclusive license with Empirico for EMP‑012, a small interfering RNA candidate in Phase I for chronic obstructive pulmonary disease (COPD), paying $85 million up front with potential for up to $745 million in total consideration. GSK framed the asset as a novel, long‑acting siRNA aimed at non‑type‑2 inflammatory COPD patients where treatment options are limited. Empirico will continue development oversight while GSK gains global rights; the candidate is described as potentially suitable for monotherapy or combination regimens. GSK’s respiratory leadership positioned the deal as complementary to the company’s diversified COPD pipeline, including biologics and small molecules. The transaction signals pharma interest in inhaled/locally delivered oligonucleotide approaches for chronic respiratory disease and provides Empirico with a near‑term commercial partner to scale development and global reach.